This clinical trial focuses on patients with acromegaly, a condition where the body produces too much growth hormone. The study evaluates a new medication called Debio 4126, which is a 12-week formulation of octreotide, compared to a placebo and other treatments. The purpose is to determine if Debio 4126 can effectively maintain normal levels of insulin-like growth factor 1 (IGF-1) in patients who have previously been treated with medications called somatostatin analogs.
The study involves three groups of participants. Some patients will receive Debio 4126 through intramuscular injection, while others will receive a placebo. The third group will receive Debio 4126 in an open-label manner, meaning both the doctor and patient know which treatment is being given. The medication will be administered every 12 weeks, and patients will be monitored for changes in their IGF-1 levels and overall health throughout the study period.
The treatment may also include other medications such as lanreotide for some participants. Throughout the study, doctors will monitor the safety of the treatment by checking various health parameters, including blood tests, vital signs, and the size of the pituitary tumor. They will also evaluate how well patients tolerate the injections by assessing any reactions at the injection site.
Austria 
Belgium 
Bulgaria 
Denmark 
Estonia 
France 
Germany 
Hungary 
Italy 
Latvia 
Lithuania 
Poland 
Romania 
Slovakia 
Spain 
Sweden 